A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2017
At a glance
- Drugs MVA-p53 (Primary) ; Gemcitabine
- Indications Ovarian cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 11 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Sep 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.